InvestorsHub Logo
Post# of 253527
Next 10
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

Re: None

Monday, 02/25/2019 10:12:25 AM

Monday, February 25, 2019 10:12:25 AM

Post# of 253527
Impressive data from MRKR here.

I suspect MRKR is going to be one of those early buyout/high premium type of situations, since the technology is impressive and they really don't have the infrastructure to advance such a complex therapy rapidly. A Novartis, Celgene/BMS, or Amgen would though.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.